Table 3 Major reported safety data from study patient population over 18 months.

From: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial

AEs, No. of participants (%)

Avacincaptad pegol 2 mg (n = 67)

Avacincaptad pegol 4 mg (n = 83)

Sham (n = 110)

Ocular SAEs, study eyea

1 (1.5)

1 (1.2)

0

Ocular SAEs, fellow eye

0

0

0

Ocular TEAEs, study eye

39 (58.2)

61 (73.5)

45 (40.9)

Ocular TEAEs, fellow eye

15 (22.4)

24 (28.9)

25 (22.7)

Study drug-related ocular TEAEs, study eye

0

0

0

Endophthalmitis

0

0

0

Intraocular inflammationa

1

0

0

Discontinuation from trial related to study drug

0

0

0

Systemic SAEs

11 (16.4)

20 (24.1)

28 (25.5)

Study drug-related systemic SAEs

0

0

0

Systemic TEAEs

41 (61.2)

53 (63.9)

66 (60.0)

Study drug-related systemic TEAEs

0

0

0

  1. AE adverse event, SAE serious adverse event, TEAE treatment-emergent adverse event.
  2. aNot drug-related per investigators.
Back to article page